Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Explore the exciting world of CRISPR Therapeutics (NASDAQ: CRSP) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market ...

Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

Barclays (LON:BARC) analyst Gena Wang maintained a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Wednesday, setting a... Oppenheimer analyst Jay Olson maintained a Buy rating on Crispr ...